Zoetis Inc. (ZTS) Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Zoetis Inc. is a global leader in the animal health industry, operating in two geographic segments: the United States and International. The company markets products for companion animals (dogs, cats, horses) and livestock (cattle, poultry, swine, fish, sheep) across approximately 45 countries. Notably, the company completed the divestiture of its medicated feed additive portfolio in October 2024, which impacts year-over-year comparisons.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) | Change |
|---|---|---|---|
| Revenue | $4,680 million | $4,551 million | +3% (Reported) / +5% (Operational) |
| Net Income | $1,349 million | $1,223 million | +10% |
| Diluted EPS | $3.02 | $2.67 | +13% |
| Operating Cash Flow | $1,073 million | $1,097 million | -2% |
| Cost of Sales Margin | 27.2% | 28.8% | Improved |
| Effective Tax Rate | 21.2% | 19.9% | +130 bps |
| Cash & Equivalents | $1,435 million | $1,987 million (Dec 2024) | -28% (QoQ) |
| Total Debt | $6,581 million | $6,570 million (Dec 2024) | Flat |
Note: Total Debt includes $1,350 million current portion and $5,231 million long-term portion.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3% year-over-year, driven by 5% operational growth. Growth was supported by price increases (~4%) and volume growth in key franchises, partially offset by a ~4% volume decrease due to the 2024 medicated feed additive divestiture. Foreign exchange headwinds reduced reported revenue growth by approximately 2%.
- Segment Performance:
- U.S. Segment: Revenue up 3% (YTD). Companion animal revenue grew 9%, while livestock revenue declined 21% primarily due to the divestiture impact.
- International Segment: Revenue up 2% (YTD), with 6% operational growth. Foreign exchange negatively impacted revenue by 4%.
- Profitability: Net income grew 10% to $1.349 billion. The effective tax rate increased to 21.2% from 19.9% due to lower U.S. foreign-derived intangible income benefits and higher discrete tax expenses.
- Restructuring: Restructuring charges decreased to $30 million (YTD 2025) from $46 million (YTD 2024). Current charges relate to asset impairments and employee terminations for transitioning innovation/manufacturing to external partners.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong operational performance with double-digit growth in companion animal products (e.g., Simparica Trio, dermatology products). The company continues to invest in R&D and business process transformation. No specific full-year 2025 financial guidance was provided in this text excerpt.
Risks and Contingencies:
- Tax Litigation: The company is under IRS audit for tax years 2017 and 2018. The IRS proposed an additional tax liability of approximately $450 million (excluding interest/penalties) related to the 2018 deemed repatriation tax. Zoetis disagrees with the position and is defending it.
- Trade Policy: New tariffs announced in early 2025 by the U.S. and reciprocal actions by other nations create uncertainty regarding product costs and demand.
- Legislative Changes: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025, extending certain tax provisions. The company is evaluating the impact on its effective tax rate and deferred tax assets.
- Environmental: Ongoing environmental litigation in Brazil regarding waste disposal at an incineration facility.
Investor Verification Checklist
- Divestiture Impact: Verify the full-year revenue impact of the medicated feed additive divestiture completed in late 2024 on livestock segment comparisons.
- Tax Exposure: Monitor the status of the IRS audit regarding the $450 million proposed adjustment and the potential impact on future tax provisions.
- Debt Maturities: Note that $1.35 billion in senior notes mature in late 2025 (Nov 2025); verify refinancing plans or cash availability for repayment.
- Share Repurchases: Confirm the remaining authorization under the $6 billion buyback program ($4.9 billion remaining as of June 30, 2025) and execution pace.
- Operational vs. Reported Growth: Distinguish between reported growth (impacted by FX) and operational growth (5% YTD) when assessing core business momentum.